Vimarsana
Biggest News Aggregation in the World

Placebo Controlled Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Placebo Controlled Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Placebo Controlled Study Today - Breaking & Trending Today

Light therapy increases brain connectivity following injury - Vimarsana News

Light therapy increases brain connectivity following injury

Low-level light therapy appears to affect healing in the brains of people who suffered significant brain injuries.

Light therapy increases brain connectivity following injury, study finds - Vimarsana News

Light therapy increases brain connectivity following injury, study finds

Low-level light therapy appears to affect healing in the brains of people who suffered significant brain injuries, according to a study published in Radiology.

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - Vimarsana News

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio - Vimarsana News

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1%...

Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio - Vimarsana News

Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs.